Can I Take Creatine with Egrifta (Tesamorelin)?

Print or save as PDF

Key numbers

  • 0.14 mg/dLAverage rise in serum creatinine from creatine across 26 studiesSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 10.75 mL/minAverage fall in creatinine-based GFR from creatine in the 26-study analysisSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 1.4 mgEgrifta SV dose, injected once daily under the skin of the abdomenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 3 to 5 g/dayMaintenance creatine dose per day in NIH ODS adult study protocolSource: ods.od.nih.gov, as cited Nov 7, 2026
  • Drug / tesamorelin: Egrifta SV 1.4 mg or Egrifta WR 1.28 mg, subcutaneous once daily [1][2]
  • Supplement / creatine monohydrate, study protocols of 3 to 5 g/day maintenance, or 3 to 6 g/day with no loading phase [5]
  • Label interaction listing / CYP450-metabolized drugs and glucocorticoids; creatine is not named in either label [1][2]
  • Creatine effect on serum creatinine / +0.13 to 0.14 mg/dL average, no change in Cr-EDTA-measured GFR [3][4]
  • Tesamorelin monitoring per label / IGF-1 and glucose [1]
  • Creatine side effects per NIH ODS / no consistent set except weight gain from water retention, about 1 to 2 kg in a month with strength training [5]
  • Creatine in kidney trials / no loss of filtration in trained adults, adults with type 2 diabetes, and sedentary men [6][7][8]

What Egrifta Is and What the Label Covers

Tesamorelin is a synthetic analog of human growth hormone-releasing factor. It binds and stimulates GRF receptors on pituitary somatotroph cells, which release more of the body's own growth hormone, and that raises IGF-1 and IGFBP-3 [1]. Egrifta SV is 1.4 mg (0.35 mL of the reconstituted solution) injected subcutaneously into the abdomen once daily, rotating sites [1]. Egrifta WR is 1.28 mg (0.16 mL) on the same schedule, and the labels state the two products are not substitutable [2].

The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label says it is not indicated for weight loss because the effect on weight is neutral, and that long-term cardiovascular safety has not been established [1].

The Egrifta Drug Interactions Section, in Full

The label lists two interaction entries. The first covers drugs metabolized by CYP450 liver enzymes: published data suggest growth hormone may alter their clearance, and the label names corticosteroids, sex steroids, anticonvulsants and cyclosporine and asks prescribers to monitor [1]. Coadministration with simvastatin changed simvastatin exposure by about -8% (AUC) and ritonavir exposure by about -9%, which the label calls no significant impact [1]. The second covers glucocorticoids: growth hormone inhibits 11-beta-HSD1, so the label says people receiving glucocorticoid replacement for hypoadrenalism may need higher maintenance or stress doses after starting Egrifta [1].

Creatine appears in neither entry, in either label [1][2]. It is sold over the counter as a dietary supplement, and a Drugs@FDA search returns no approved drug application with creatine as the active ingredient [5][9].

The Creatinine Question

Creatine is not creatinine, but the body converts one into the other, and creatinine is the waste product standard kidney blood tests measure [4]. Pooled randomized trials put the average rise in serum creatinine at 0.13 mg/dL (19 RCTs plus one crossover study; 95% CI 0.07 to 0.18) [3] and 0.14 mg/dL (26 studies, 1,036 people; 95% CI 0.05 to 0.22) [4].

In the 26-study analysis, creatinine-based GFR fell by an average of 10.75 mL/min (95% CI -17.48 to -4.02), while GFR measured by Cr-EDTA did not change significantly (+5.89 mL/min, 95% CI -0.30 to 12.08); urea, albuminuria and proteinuria were unchanged [4]. The authors read the pattern as altered creatinine metabolism rather than kidney injury [4].

Trials that measured filtration directly point the same way. In resistance-trained adults eating at least 1.2 g/kg/day of protein, 12 weeks of creatine (20 g/day for 5 days, then 5 g/day) gave 51Cr-EDTA clearance of 101.4 to 108.8 mL/min/1.73 m2 versus 103.3 to 106.7 on placebo (group-by-time p=0.64) [6]. In adults with type 2 diabetes over 12 weeks, 51Cr-EDTA clearance was 90.4 to 96.1 on creatine versus 97.9 to 96.4 on placebo (p=0.58), with proteinuria and albuminuria unchanged [7]. In 18 sedentary men taking about 10 g/day for 3 months, cystatin C fell on both creatine and placebo, showing no sign of reduced filtration [8]. One case report describes a 24-year-old weightlifter who developed biopsy-proven acute interstitial nephritis while taking creatine plus several other supplements and recovered fully after stopping all of them; creatine cannot be singled out [12].

The practical point: a creatinine-based eGFR can under-read kidney function in someone taking creatine, so whoever orders the kidney panel should know creatine is in use [4].

Questions worth asking

Choose the questions you want to keep

Kidney Function and Tesamorelin

The monitoring tests the Egrifta labels single out are IGF-1 and glucose [1][2]. The labels also state that tesamorelin pharmacokinetics in people with renal or hepatic impairment have not been established [1][2].

What the Label Asks Prescribers to Watch

IGF-1 is the main one. Among patients treated for 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3; at 52 weeks, the figures were 34% and 23% [1]. The label asks prescribers to monitor IGF-1 and consider stopping for persistent elevations such as above 3 SDS, particularly if the fat reduction is not robust [1].

Glucose is the second. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26 (hazard ratio about 3.3, 95% CI 1.4 to 9.6), and the label calls for evaluating glucose before and during treatment [1].

Fluid retention is a labeled warning and shows up as edema, joint pain and carpal tunnel syndrome [1]. Injection site reactions occurred in 25% on tesamorelin versus 14% on placebo in the first 26 weeks [1]. Hypersensitivity reactions occurred in 4%, and the label says to seek prompt medical attention and discontinue treatment if one is suspected [1].

Creatine has a different kind of water-related effect. NIH ODS reports no consistent set of side effects except weight gain from water retention, about 1 to 2 kg in a month when creatine is combined with strength training [5].

Creatine and Growth Hormone

In 11 men, five days of creatine at 20 g/day did not change the growth hormone or testosterone response to a heavy resistance-training session [13]. That study measured growth hormone, testosterone and cortisol responses, not IGF-1. In the 412-patient tesamorelin trial, IGF-1 rose 81.0% on tesamorelin versus a 5.0% fall on placebo over 26 weeks [10].

Dosing

NIH ODS describes two creatine monohydrate study protocols in adults: a loading phase of 20 g/day in four 5 g portions for 5 to 7 days followed by 3 to 5 g/day, or about 3 to 6 g/day for 3 to 4 weeks without a loading phase [5].

The International Society of Sports Nutrition position stand calls short- and long-term supplementation, up to 30 g/day for 5 years, safe and well tolerated in healthy people and some patient groups. That is a society position paper, not a regulator's finding [14].

Egrifta is dosed by its own label: SV 1.4 mg once daily or WR 1.28 mg once daily, both into the abdomen with site rotation, and the two products are not interchangeable [1][2].

Creatine monohydrate is the form with the most research [5]; unflavored creatine monohydrate powder is one example.

Kidney Disease, Heat and Other Limits

Few creatine trials enrolled people with kidney disease, and long-term safety in advanced kidney disease is not established by these data [4]. In a heat-stress trial, 12 active men who took 21.6 g/day for 7 days, lost 2% of body mass and then completed an 80-minute exercise test at 33.5 C had no difference in rectal temperature (39.3 vs 39.4 C) or other thermoregulatory responses compared with placebo [15].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the Egrifta labels, which two monitoring tests are singled out?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Can I take creatine with Egrifta (tesamorelin)?
Neither EGRIFTA SV nor EGRIFTA WR names creatine in its drug interactions section, which covers CYP450-metabolized drugs and glucocorticoids [1][2]. The practical issue is that creatine raises serum creatinine by about 0.13 to 0.14 mg/dL on average without changing measured GFR, so kidney blood tests read differently in someone taking it [3][4].
Will creatine make my creatinine look high while on tesamorelin?
Creatine alone does that: pooled trials show a 0.13 to 0.14 mg/dL average rise in serum creatinine with no change in GFR measured by Cr-EDTA clearance [3][4]. A creatinine-based eGFR can therefore under-read kidney function in someone taking creatine [4].
Does creatine change growth hormone or IGF-1?
In 11 men, five days of creatine at 20 g/day did not change the growth hormone or testosterone response to heavy resistance training; that study did not measure IGF-1 [13]. Tesamorelin raises IGF-1 substantially: 81.0% over 26 weeks versus a 5.0% fall on placebo in the 412-patient trial [10].
Is creatine hard on the kidneys?
Trials that measured filtration directly found no loss: 51Cr-EDTA clearance was unchanged over 12 weeks in resistance-trained adults and in adults with type 2 diabetes, and cystatin C fell over 3 months in sedentary men [6][7][8]. Few of these trials enrolled people with kidney disease, and long-term safety in advanced kidney disease is not established [4].
Is a creatine loading phase required?
NIH ODS describes an alternative protocol of about 3 to 6 g/day for 3 to 4 weeks with no loading phase, alongside the 20 g/day for 5 to 7 days option [5]. Creatine monohydrate is the form used in most of the research [5].
Show all 15 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  2. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  3. Tsiaras A, Loufopoulos G, Theodoridis X, Liakopoulos V, Poulia KA, Chourdakis M. The Effect of Creatine Supplementation on Kidney Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Ren Nutr. 2026.
  4. de Souza Almeida A, da Silva LOD, Takahasi BNA, Terada BD, Gonçalves FGA, Porto BC, et al. Impact of creatine supplementation on kidney health: a systematic review and meta-analysis. Int Urol Nephrol. 2026.
  5. National Institutes of Health.
  6. Lugaresi R, Leme M, de Salles Painelli V, Murai IH, Roschel H, Sapienza MT, et al. Does long-term creatine supplementation impair kidney function in resistance-trained individuals consuming a high-protein diet?. J Int Soc Sports Nutr. 2013;10(1):26.
  7. Gualano B, de Salles Painelli V, Roschel H, Lugaresi R, Dorea E, Artioli GG, et al. Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial. Eur J Appl Physiol. 2011;111(5):749-56.
  8. Gualano B, Ugrinowitsch C, Novaes RB, Artioli GG, Shimizu MH, Seguro AC, et al. Effects of creatine supplementation on renal function: a randomized, double-blind, placebo-controlled clinical trial. Eur J Appl Physiol. 2008;103(1):33-40.
  9. Drugs@FDA: FDA-Approved Drugs.
  10. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
  11. Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22.
  12. Thorsteinsdottir B, Grande JP, Garovic VD. Acute renal failure in a young weight lifter taking multiple food supplements, including creatine monohydrate. J Ren Nutr. 2006;16(4):341-5.
  13. Eijnde BO, Hespel P. Short-term creatine supplementation does not alter the hormonal response to resistance training. Med Sci Sports Exerc. 2001;33(3):449-53.
  14. Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017;14:18.
  15. Watson G, Casa DJ, Fiala KA, Hile A, Roti MW, Healey JC, et al. Creatine use and exercise heat tolerance in dehydrated men. J Athl Train. 2006;41(1):18-29.
Evidence overview for Can I Take Creatine with Egrifta (Tesamorelin)?